[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Tianjin Anding Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":149},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,45,70,101,122],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100633192","investigation-on-suicide-risk-factors-of-patients-with-mood-disorders-100633192",false,"NCT07523490","Investigation on Suicide Risk Factors of Patients With Mood Disorders","Investigation on Suicide Risk Factors of Patients With Mood Disorders in China","Inclusion Criteria:\n\n1. Age: 16 to 60 years old;\n2. seeing a doctor in a psychiatric clinic or a general hospital;\n3. Willing to cooperate in this research project;\n4. Sign the informed consent form (minors also need to obtain the informed consent signature of the guardian);\n5. Meet the diagnostic criteria of ICD-11 mood disorder.\n\nExclusion Criteria:\n\n1. unable to understand the contents of the questionnaire;\n2. Serious organic diseases such as cardiovascular disease, brain disease, liver disease and kidney disease, and weak body, which affect the respondents of the questionnaire;\n3. Other circumstances that make it impossible or unwilling to cooperate with the completion of the questionnaire.","ALL","16 Years","60 Years",{"count":20,"type":21},300,"ESTIMATED","3 Months","OBSERVATIONAL","This study investigates the level and distribution of suicide risk and learned suicide ability of patients with mood disorders, investigates the related risk factors of suicide and suicide ability formation of patients with mood disorders from multiple dimensions (biological, psychological, social and clinical perspectives) and clarifies their importance, forms a list of suicide risk factors, and establishes a prediction model of learned suicide ability formation. Upon enrollment, participants will undergo comprehensive assessments including blood and urine sample collection and scale evaluation. The collection of scientific blood and urine is mainly used for the exploration of molecular mechanism of disease occurrence and development, the discovery and verification of biomarkers. Scale evaluation includes: Beck Scale for Suicide Ideation , Columbia Suicide Severity Rating Scale,, Hamilton Depression Rating Scale , Hamilton Anxiety Rating Scale, PHQ-9, GAD-7, Personal and Social Function Scale , Schihan Disability Scale , Emotional Adjustment Difficulty Scale , Acquired Capability for Suicide Scale, Interpersonal Needs Questionnaire , Ottawa Self-Injury Scale, Chinese version of Stress Perception Scale and Beck Hopelessness Scale . Follow-up was carried out for 3 months, including whether suicide\u002Fself-injury occurred, current status, and some baseline questionnaires (such as BSI-CV, GAD-7, PHQ-9, HAMD-17,HAMA, etc.).",[26,27],"Mood Disorders","Suicide",[26,29,30,31],"suicide","Biological Mechanism","prediction model","RECRUITING","2026-04-18",{"date":35,"type":36},"2026-04-22","ACTUAL",{"date":38,"type":36},"2025-12-31",{"date":40,"type":21},"2027-09-30",{"name":42,"class":43},"Tianjin Anding Hospital","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":44},"100556392","efficacy-tolerability-and-cognitive-effects-of-deep-transcranial-magnetic-stimulation-for-bipolar-depression-100556392","NCT06524505","Efficacy, Tolerability, and Cognitive Effects of Deep Transcranial Magnetic Stimulation for Bipolar Depression","Efficacy, Tolerability, and Cognitive Effects of Deep Transcranial Magnetic Stimulation for Bipolar Depression: a Double-blind, Randomized Controlled Trial","Inclusion Criteria:\n\nConfirmed diagnosis of bipolar depression;\n\n* age between 18 and 65 years;\n* a 17-item Hamilton Depression Rating Scale (HDRS-17) score \\>= 17,\n* a stable pharmacological regimen maintained for at least 4 weeks prior to the beginning of the treatment phase ;\n* for participants who had previously received antidepressant therapy, a minimum 4-week washout period followed by re-evaluation.\n\nExclusion Criteria:\n\n* a lifetime history of other psychiatric disorders, neurological diseases, or severe brain injury;\n* receipt of electroconvulsive therapy, rTMS, transcranial direct current stimulation, transcranial alternating current stimulation, or other neurostimulation treatments within the previous 3 months;\n* contraindications to magnetic stimulation, including epilepsy, cardiovascular disorders, or metallic implants in the head;\n* the presence of hypomanic\u002Fmanic symptoms at baseline or a score greater than 12 on the Young Mania Rating Scale (YMRS);\n* pregnancy or lactation.","18 Years","65 Years",{"count":55,"type":21},100,"INTERVENTIONAL",[58],"NA","The aim of this study is to evaluate the feasibility and efficacy of deep transcranial magnetic stimulation (dTMS) as an add-on treatment for bipolar depression. Meanwhile, we aim to evaluate the effect of dTMS on cognitive function of bipolar depressive patients. We hypothesize dTMS would improve depressive symptoms and cognitive function in bipolar disorder.",[61],"Bipolar Depression","2026-02-24",{"date":64,"type":36},"2026-02-27",{"date":66,"type":36},"2024-08-01",{"date":68,"type":21},"2026-02",{"name":42,"class":43},{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":56,"phases":80,"briefSummary":81,"conditions":82,"keywords":86,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":4},"100623194","pqq-for-cognitive-and-negative-symptoms-100623194","NCT07393464","PQQ for Cognitive and Negative Symptoms","The Efficacy and Safety of Pyrroloquinoline Quinone add-on Treatment for Negative and Cognitive Symptoms in Chronic Schizophrenia","Inclusion criteria:\n\nEligible male and female patients aged 18 to 50 years, diagnosed with schizophrenia according to the criteria outlined in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5), will be included in the study. Participants are required to meet the following criteria: a Positive and Negative Syndrome Scale (PANSS) total scores of ≥ 60 (indicating an active phase of the illness), a PANSS negative subscale scores of ≥ 20, and a duration of illness of at least 2 years (indicating chronic schizophrenia). Additionally, participants must have been on a stable dose of antipsychotic medication for a minimum of 6 weeks prior to enrollment, and the use of antioxidants or anti-inflammatory medications is prohibited within 2 weeks preceding enrollment.\n\nExclusion criteria:\n\nPatients with comorbid psychiatric disorders as defined by the DSM-5, such as substance abuse or dependence (excluding nicotine), or intellectual disability (IQ \\\u003C 70); those with significant depressive symptoms, defined as a score ≥14 on the 17-item Hamilton Depression Rating Scale (HAMD-17) or ≥ 4 on the depression item of PANSS; individuals with severe medical or neurological conditions, or those unable to communicate effectively; patients with a known allergy to PQQ disodium salt, or who are pregnant, breastfeeding, or have severe hepatic or renal impairment; women of childbearing potential who are not using reliable contraception; patients who have received modified electroconvulsive therapy (MECT) or other physical treatments within six months prior to enrollment; and those currently receiving treatments that cannot be discontinued, including antidepressants, mood stabilizers, antihistamines, or combination therapy with two or more antipsychotics (except for low-dose aripiprazole, ≤ 5 mg\u002Fday, used solely for prolactin reduction).\n\nAdditional exclusion criteria for participants undergoing fMRI scanning:\n\nParticipants are required to complete a comprehensive safety questionnaire addressing potential risks associated with exposure to a 3-Tesla magnetic field and the MRI environment. MRI-specific exclusion criteria include: the presence of MRI-incompatible implants (e.g., cochlear implants, insulin pumps, pacemakers, or other metallic implants); a history of possible intraocular metallic foreign bodies due to manual labor without appropriate eye protection; tattoos containing red pigments; claustrophobia; or unwillingness to be informed of any incidental structural brain abnormalities detected during the scan.","50 Years",{"count":79,"type":21},70,[58],"Schizophrenia is a complex mental disorder characterized by a range of symptoms, including negative symptoms and cognitive impairments. Recent research has indicated the potential benefits of targeting mitochondrial dysfunction, oxidative stress, and inflammatory responses in alleviating symptoms of schizophrenia. However, the results remain inconsistent across various studies. This study aims to evaluate the efficacy of Pyrroloquinoline quinone (PQQ) in reducing negative symptoms and improving cognitive function in patients with chronic schizophrenia. The investigation will focus on changes in severity scores from baseline to endpoint, as well as during an eight-week follow-up period. A double-blind, randomized controlled trial will be conducted involving participants diagnosed with chronic schizophrenia. Participants will be randomly assigned to receive either PQQ or a matched placebo. Data will be collected through questionnaires and neuroimaging techniques, including resting-state scans and multimodal tasks to assess functional connectivity and activation in target brain regions. Statistical analyses will include descriptive statistics, voxel-by-voxel multiple regression, and linear mixed models to account for repeated measurements. Additionally, potential moderating effects of demographic factors such as age and gender will be examined using ANCOVAs. The study will also monitor adverse events and ensure participant safety through a rigorous reporting and unblinding procedure. It is hope to provide insights into the therapeutic potential of PQQ in managing schizophrenia symptoms, contributing to the development of more effective treatment strategies for this challenging condition.",[83,84,85],"Schizophrenia","Cognitive Symptoms","Negative Symptoms",[87,88,89,90,91],"cognitive symptom","negative symptom","schizophrenia","Pyrroloquinoline Quinone","MCCB","NOT_YET_RECRUITING","2026-02-06",{"date":95,"type":36},"2026-02-10",{"date":97,"type":21},"2026-02-15",{"date":99,"type":21},"2028-04-15",{"name":42,"class":43},{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":107,"sex":16,"minAge":52,"maxAge":53,"enrollmentInfo":108,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":109,"conditions":110,"keywords":111,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":121,"locationsCount":44},"100603642","study-on-the-role-and-mechanism-of-plasma-exosome-micrornas-in-cognitive-impairment-in-first-episode-schizophrenia-100603642","NCT07139171","Study on the Role and Mechanism of Plasma Exosome microRNAs in Cognitive Impairment in First-episode Schizophrenia","Inclusion Criteria:\n\n* Healthy volunteers matched to the patient group on sex, age, and education level;\n* No family history of psychiatric disorders among first- or second-degree relatives (two generations);\n* Ethnic Han Chinese;\n* Able and willing to provide written informed consent.\n\nExclusion Criteria:\n\n* Any serious physical illness, including but not limited to uncontrolled hypertension, severe cardiovascular, cerebrovascular, pulmonary, thyroid, or metabolic disease, diabetes, epilepsy, or metabolic syndrome;\n* Current or past diagnosis of substance-induced psychotic disorder, delusional disorder, brief psychotic disorder, or mood disorder with psychotic features;\n* Pregnancy or breastfeeding;\n* Any condition that would interfere with the ability to give informed consent or complete study procedures.",true,{"count":20,"type":21},"Schizophrenia is a severe mental illness characterised by positive symptoms, negative symptoms, and cognitive symptoms. In recent years, an increasing number of doctors and scholars have focused on cognitive symptoms; however, the mechanisms underlying cognitive impairment remain unclear. Recently, exosome research methods have provided new avenues for investigation. This study applies exosome research methods to first-episode, drug-naive schizophrenia patients to explore gene expression changes associated with cognitive impairment and gain a deeper understanding of the mechanisms underlying cognitive impairment. By integrating basic research with clinical findings, we aim to further investigate the molecular mechanisms underlying cognitive impairment in schizophrenia patients, identify potential intervention targets, and provide insights for future drug development.",[83],[89,112,113,114],"cognitive funciton","exosome","microRNA","2025-09-19",{"date":117,"type":36},"2025-09-24",{"date":119,"type":36},"2022-11-11",{"date":38,"type":21},{"name":42,"class":43},{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":4,"eligibilityCriteria":128,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":129,"enrollmentInfo":130,"targetDuration":4,"studyType":56,"phases":132,"briefSummary":133,"conditions":134,"keywords":137,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":44},"100578563","tacs-on-high-inflammatory-and-refractory-depression-100578563","NCT06812923","TACS on High-inflammatory and Refractory Depression","The Study on Effectiveness and Mechanisms of Transcranial Alternating Current Stimulation in Treating Increased Inflammatory Activity Refractory Depression","Inclusion Criteria:\n\n* (1) Aged between 18 and 55 years; (2) Diagnosed with depression through a structured clinical interview by a psychiatrist using the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5); (3) A total score of 17 or above on the 17-item Hamilton Depression Rating Scale (HAMD-17), with a score of 2 or more on item 1 (depression); (4) CRP level between 0.85-10 mg\u002FL; (5) DM-TRD score of at least 12.5; (6) Stable use of treatment medications (antidepressants, antipsychotics) for at least 2 weeks during the current depressive episode; (7) Able to understand and sign the informed consent form.\n\nExclusion Criteria:\n\n* (1) A history of current or past seizures, epilepsy, hydrocephalus, central nervous system tumors, or acute brain injury and infections; (2) A score of 3 or 4 on item 3 of the HAMD-17, or a history of suicidal behavior with significant suicide risk; (3) Received electroconvulsive therapy (ECT), modified electroconvulsive therapy (MECT), transcranial magnetic stimulation (TMS), transcranial direct current stimulation (tDCS), tACS, or other neuromodulation treatments within one month prior to enrollment; (4) Pregnant or breastfeeding women; (5) Patients with any severe organic disease or in an unstable condition due to organic disease; (6) Used anti-inflammatory drugs for more than 7 days cumulatively in the last 2 months, or used immunosuppressive drugs, such as corticosteroids; (7) Suffering from chronic infectious or autoimmune diseases, such as lupus, enteritis, hepatitis, etc.; (8) A history of substance dependence or substance abuse.","55 Years",{"count":131,"type":21},52,[58],"This study is a randomized controlled trial with a duration of 12 weeks (4 weeks of intervention + 8 weeks of follow-up). The participants are patients with treatment-resistant depression (TRD) and high inflammatory activity (n=52). The study aims to clarify the effectiveness of 15mA, 77.5Hz transcranial alternating current stimulation (tACS) in treating TRD with high inflammatory activity by comparing the changes in depressive symptoms and biological markers after active tACS stimulation versus sham stimulation. Additionally, the study seeks to explore potential underlying mechanisms of action.",[135,136],"Treatment Resistant Depression (TRD)","Inflammation",[138,139,140],"treatment resistant depression","transcranial Alternating Current Stimulation","C-reactive protein","2025-02-02",{"date":143,"type":36},"2025-02-06",{"date":145,"type":36},"2025-01-01",{"date":147,"type":21},"2028-12-31",{"name":42,"class":43},""]